Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Heparin sodium
Drug ID BADD_D01061
Description Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Indications and Usage Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin therapy in patients with unstable angina and/or non-Q wave myocardial infarctions (i.e. non-ST elevated acute coronary artery syndrome) who are on platelet glycoprotein (IIb/IIIa) receptor inhibitors. Additionally, it is used to prevent clotting during dialysis and surgical procedures, maintain the patency of intravenous injection devices and prevent in vitro coagulation of blood transfusions and in blood samples drawn for laboratory values.
Marketing Status Prescription; Discontinued
ATC Code B01AB01; C05BA03; S01XA14
DrugBank ID DB01109
KEGG ID D02112
MeSH ID D006493
PubChem ID 92044406
TTD Drug ID D0UX6Z
NDC Product Code 63323-262; 0409-7620; 0409-1402; 63323-276; 67957-0001; 63323-540; 25021-402; 51662-1460; 66298-5197; 63323-459; 67457-383; 71288-404; 46655-1224; 0641-6199; 71288-403; 66298-5191; 72572-255; 51662-1409; 0641-2450; 57262-300; 63323-118; 63323-543; 0069-0137; 63323-915; 71288-419; 55154-2380; 55154-6985; 71288-424; 0641-6204; 0264-5705; 0641-0400; 72572-250; 71839-117; 55154-8138; 44055-001; 63739-901; 0641-0410; 63323-047; 71839-118; 0338-0433; 70398-0001; 76392-501; 63739-920; 71288-425; 52584-400; 57262-370; 63739-900; 63739-975; 76045-108; 67457-602; 25021-403; 51927-3286; 0409-2720; 0641-0391; 0641-2460; 67457-385; 71288-421; 55154-9585; 63739-964; 71288-405; 55154-8131; 63739-942; 76392-101; 52584-111; 63323-542; 67457-603; 55154-2827; 63323-518; 0409-7651; 51662-1411; 0404-9979; 31387-100; 0338-0428; 0069-0058; 63739-986; 0338-0431; 71288-400; 0069-0043; 51662-1434; 25021-401; 0409-7650; 44498-002; 25021-404; 82051-003; 71288-406; 63323-523; 63739-953; 71288-402; 67957-0002; 0409-2721; 52221-123; 63323-522; 68083-136; 55154-9583; 25021-400; 0069-0059; 52221-101; 67457-372; 63323-517; 65219-066; 81565-203; 63323-519; 63739-931; 71288-422; 0404-9872; 71288-401; 71288-423; 51552-1595; 28955-001; 53484-001; 0409-1316; 81952-111; 0409-2723; 55154-5130; 67583-018; 67457-374; 0409-7793; 67457-373; 67457-384; 52584-402; 81952-115; 71288-420; 0338-0424; 51662-1486; 42455-001; 60870-0249
Synonyms Heparin | Unfractionated Heparin | Heparin, Unfractionated | Heparinic Acid | Liquaemin | Sodium Heparin | Heparin, Sodium | Heparin Sodium | alpha-Heparin | alpha Heparin
Chemical Information
Molecular Formula C26H42N2NaO37S5+
CAS Registry Number 9041-08-1
SMILES CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C( C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O.[Na+]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Adrenal haemorrhage24.07.01.023; 12.01.02.006; 05.01.03.002--Not Available
Alanine aminotransferase13.03.01.031--Not Available
Alanine aminotransferase increased13.03.01.003--
Alopecia23.02.02.001--
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Aspartate aminotransferase increased13.03.01.006--
Asthma22.03.01.002; 10.01.03.010--Not Available
Blood aldosterone decreased13.10.09.007--Not Available
Burning sensation17.02.06.001; 08.01.09.029--Not Available
Chills15.05.03.016; 08.01.09.001--
Erythema23.03.06.001--Not Available
Haematoma24.07.01.001--
Headache17.14.01.001--
Hypersensitivity10.01.03.003--
Injection site irritation12.07.03.027; 08.02.03.027--Not Available
Lacrimation increased06.08.02.004--
Nausea07.01.07.001--
Osteoporosis15.02.03.002; 14.04.04.002--
Pain08.01.08.004--
Priapism21.03.01.005--Not Available
Prinzmetal angina24.04.04.015; 02.02.02.019--Not Available
Pyrexia08.05.02.003--
Retroperitoneal haemorrhage24.07.01.017; 07.07.02.002--
Rhinitis22.07.03.006; 11.01.13.004--
Shock24.06.02.002--Not Available
Skin irritation23.03.04.009--Not Available
Skin necrosis23.03.03.011--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombosis24.01.01.006--Not Available
Ulcer08.03.06.001--Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages